Development of ELISA-based methods to measure the anti-malarial drug chloroquine in plasma and in pharmaceutical formulations

Insaf F Khalil, Michael Alifrangis, Camilla Recke, Lotte C Hoegberg, Anita Ronn, Ib C Bygbjerg, Claus Koch

Research output: Contribution to journalJournal articleResearchpeer-review

17 Citations (Scopus)

Abstract

In Central and South America and Eastern and Southern Africa, Plasmodium vivax infections accounts for 71-81% and 5% of malaria cases, respectively. In these areas, chloroquine (CQ) remains the treatment of choice for P. vivax malaria. In addition, CQ has recently proven to be an effective HIV-1 therapeutic agent. There is a dire need to continue monitoring quality of CQ as there is a major influx of substandard and fake formulations into malaria-endemic countries. The use of fake/substandard drugs will result in sub-therapeutic levels endangering the patient and possibly select for parasite resistance. The aim of this study was to develop an inexpensive, simple antibody-based ELISA to measure CQ concentrations in tablets and in plasma.
Original languageEnglish
JournalMalaria Journal
Volume10
Pages (from-to)249
ISSN1475-2875
DOIs
Publication statusPublished - 1 Jan 2011

Cite this